Clinical trials: Chronic Obstructive Pulmonary
Pulmonary Disease, Chronic Obstructive
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, 3-way crossover study to evaluate the lung function response to UMEC 62.5 mcg, VI 25 mcg, and UMEC/VI 62.525 mcg, administered once-daily via a novel dry powder inhaler (NDPI) over…
- Trial name
- NCT02014480
- Testing
- Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg
- Where
- 21 sites in Slovakia, Ukraine
- Volunteers
- 207 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease
Relatively little information is available about the effects of salmeterol/fluticasone combination and fluticasone alone in COPD patients with a partial reversible pulmonary obstruction.
- Trial name
- NCT00549146
- Testing
- fluticasone propionate/salmeterol 250/50 DISKUS combination product, fluticasone propionate DISKUS 500mcg
- Where
- 17 sites in Netherlands
- Volunteers
- 290 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
Efficacy of Fluticasone/Formoterol in COPD Treatment. The Effect study.
- Trial name
- NCT01946620
- Testing
- Flutiform, Formoterol
- Where
- 15 sites in Bulgaria, Germany and 13 more
- Volunteers
- 1,767 people
- Sponsor
- Mundipharma Research Limited
COPD
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
The goal of this clinical trial is to compare the acute bronchodilator effect of pMDI formed Ipratropium / Levosalbutamol 20 mcg / 50 mcg fixed dose combination or pMDI formed Salbutamol 100 mcg Inhaler and Ipratropium 20 mcg…
- Trial name
- NCT06040424
- Testing
- Ipratropium / Levosalbutamol Fixed Dose Combination, Ipratropium + Levosalbutamol Free Dose Combination
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
COPD
Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population
The DISCOVER TLD study is a multicenter, prospective, single-arm study designed to record the clinical outcomes of the CE-marked Nuvaira™ Lung Denervation System, in a subset of its CE-marked approved indication.
- Trial name
- DISCOVER TLD (NCT03213080)
- Testing
- Targeted Lung Denervation (TLD)
- Sponsor
- Nuvaira, Inc.
Chronic Obstructive Pulmonary Disease
Post Marketing Surveillance of Roflumilast in Korea
The purpose of this study is to evaluate the safety and efficacy of roflumilast in the real-use conditions with its registered indications.
- Trial name
- NCT02068456
- Testing
- Roflumilast
- Where
- South Korea
- Volunteers
- 1,837 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with…
- Trial name
- NCT02164513
- Testing
- fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
- Where
- 998 sites in United States, Argentina and 35 more
- Volunteers
- 10,355 people
- Sponsor
- GlaxoSmithKline
COPD
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
This clinical pharmacology study is performed to evaluate the total systemic exposure and the lung availability of CHF 5993 DPI and pMDI with and without valved holding chamber, in healthy volunteers.
- Trial name
- NCT02743013
- Testing
- CHF 5993 100/6/12,5 pMDI, CHF 5993 100/6/12,5 DPI Test 1, CHF 5993 100/6/12,5 DPI Test 2
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Lung Neoplasms, Pulmonary Disease, Chronic Obstructive
A Study of Smoking Cessation Patterns in Participants Undergoing Lung Surgery
The purpose of this study is to assess the current smoking status and smoking cessation attempts among smokers or recent smoking quitters during the perioperative period, to describe postoperative pulmonary complications (PPCs)…
- Trial name
- CHAMPION (NCT04313361)
- Testing
- No intervention
- Where
- 3 sites in China
- Volunteers
- 290 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Hepatitis B, Chronic (CHB)
Study of AHB-171 in Chronic Hepatitis B Participants
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated…
- Trial name
- NCT07630727
- Testing
- AHB-171 Injection
- Where
- 10 sites in China
- Volunteers
- 138 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Obstructive Pulmonary Disease
Unrefined Salmon Oil as Dietary Supplement in Patient With Chronic Obstructive Pulmonary Disease
Research has over decades showed that marine food carries nutritional characteristics that promote human health. As seen in epidemiological studies and based on in vitro and in vivo studies, it is hypothesized that unrefined…
- Trial name
- NCT05130294
- Testing
- CARDIO®
- Where
- Norway
- Sponsor
- Hofseth Biocare ASA
Asthma, Chronic Obstructive Pulmonary Disease COPD
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men
This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics [PD]) and how the body affects the drug…
- Trial name
- NCT02645253
- Testing
- AZD7594 inhalation powder (200 μg), AZD7594 inhalation powder (400 μg), AZD7594 pressurized inhalation suspension (200 μg)
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease
To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
- Trial name
- NCT00465959
- Testing
- trospium chloride inhalation powder (TrIP)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Chronic Obstructive Pulmonary Disease
REported Outcomes in COPD With Trixeo in Real worlD in Germany
Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms (including breathlessness, cough, and sputum production), which has a substantial impact on health-related quality of life (HRQoL).
- Trial name
- RECORD (NCT05311306)
- Where
- 62 sites in Germany
- Volunteers
- 475 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
European Non-interventional Study in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study is investigating how patients with severe stable state COPD perceive the variability of their symptoms throughout the day, the week and the year; the impact of these variations on their daily activities or sleep…
- Trial name
- NCT00722267
- Where
- 606 sites in Austria, Belgium and 15 more
- Volunteers
- 7,400 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
Traumatic Brain Injury
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure…
- Trial name
- NCT05951777
- Testing
- Autologous HB-adMSCs, Normal Saline
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- Hope Biosciences LLC
Chronic Obstructive Pulmonary Disease
Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to obtain additional data on efficacy and safety of Rengalin in the treatment of cough in patients with stable obstructive pulmonary disease
- Trial name
- NCT03159091
- Testing
- Rengalin
- Where
- 18 sites in Russia
- Volunteers
- 238 people
- Sponsor
- Materia Medica Holding
Chronic Obstructive Pulmonary Disease
A Cross-sectional Study of COPD and Symptom Variability in MEA Countries
This non-interventional study aims at assessing stable GOLD C and D COPD patient's perception of daily and weekly symptoms variability and their impact on daily activities.
- Trial name
- COPVAR (NCT03425760)
- Volunteers
- 3,254 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
- Trial name
- PRESTO (NCT07082738)
- Testing
- AZD6793
- Where
- 367 sites in United States, Argentina and 22 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.